Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three agents: - **Norepinephrine** is a catecholamine neurotransmitter and hormone that acts primarily on alpha- and beta-adrenergic receptors, leading to vasoconstriction and increased blood pressure. It is used clinically as a sympathomimetic agent for the management of acute hypotensive states such as septic shock[4][5]. - **L-NAME (N^G^-Nitro-L-arginine methyl ester)** is an inhibitor of nitric oxide synthase (NOS), thereby reducing the production of nitric oxide, which leads to vasoconstriction by preventing vascular smooth muscle relaxation. - **Ascorbic acid (Vitamin C)** serves as an antioxidant and enzymatic cofactor. In this context, it enhances norepinephrine synthesis by acting as a cofactor for dopamine β-hydroxylase, the enzyme that converts dopamine to norepinephrine[1][2]. Ascorbic acid also protects cells from oxidative stress during catecholamine synthesis. This combination may be used in experimental or research settings to study vascular tone regulation, catecholamine biosynthesis, or oxidative stress responses. There are no known approved pharmaceutical products containing all three components together; their use in combination would be investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norepinephrine + L-NAME + ascorbic acid.